Now Playing
Opinion|Videos|January 8, 2025
Future Research Directions in Metastatic Uveal Melanoma
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), explore potential future research directions in metastatic uveal melanoma.
Advertisement
Episodes in this series
Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), outline important future research priorities in metastatic uveal melanoma, including optimization of liver-directed modalities, next-generation immunotherapies, and biomarker-driven patient selection. They emphasize the need for continued innovation to improve survival outcomes and broaden effective treatment options. Forschner and Khan close the program by underscoring the importance of collaborative research efforts.
Advertisement
Related to this article
First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.
The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.
A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.
Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.
Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.
Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
Dr Felip on Sequencing Next-Generation ROS1 TKIs After Progression in NSCLC
5